| Sign In to gain access to subscriptions and/or personal tools. |
Interacting with drugs used in oncology: an Alberta Cancer Board initiativePharmacy Department, Cross Cancer Institute, 11560-University Avenue, Edmonton, Alberta, Canada, T6G 1Z2
Pharmacy Department, Cross Cancer Institute, 11560-University Avenue, Edmonton, Alberta, Canada, T6G 1Z2
Pharmacy Department, Cross Cancer Institute, 11560-University Avenue, Edmonton, Alberta, Canada, T6G 1Z2 Objective. The Alberta Cancer Board (ACB) Pharmacy recognized the importance of having a sound knowledge of drug interactions with anti-neoplastic agents. A pharmacy student was given the task of surveying ACB pharmacists for published literature and Internet sources used most often as sources of drug interaction information during medication order review and evaluation of patient profiles. The goal was to extract information from these sources and integrate it into a concise ACB drug interaction database, which lists the actual and potential antineoplastic drug-drug, drug-disease, drug-natural products and drug-food interactions. The antineoplastic agents identified and examined were part of the ACB Out-patient Cancer Drug Benefit Program (OCDBP) (August 2002). Equipped with this information and using their clinical expertise, pharmacists can play an important role in the medical management of patients with cancer. Data sources. The student collected information from literary and remote sources used most often by ACB pharmacists. Study selection. ACB pharmacists were surveyed for published literature and Internet sources that contained drug interaction information on antineoplastics used most often during medication order review, patient counselling sessions and when responding to drug information requests. The contributors of these information sources claim to have reviewed existing references and thus the student relied on the accurate reporting of their findings instead of collecting data from the original works. The drugs reviewed for the purpose of the study were taken from the ACB OCDBP. Data extraction. There was an extensive data collection process. Dorland’s definition of a drug interaction was adopted. The student determined a potential interaction based on the words `may’ or `risk’ found in the statement of the interaction. The student extracted the drug interaction information into tables and a sample of 10 of 87 drugs from the ACB OCDBP are presented in this paper. A complete guide of the ACB drug interaction index can be obtained from the ACB Pharmacy. Data synthesis. Actual and potential antineo-plastic drug-drug, drug-disease, drug-natural products and drug-food interactions are summarized in tables. The information collected was as current as the date that the data were extracted. The determination of clinical significance relies on the expertise of the pharmacist or other healthcare professional. Moreover, the data contained in the tables is representative of the information collected exclusively from sources used most often by ACB pharmacists and therefore is only one source of drug interaction information. Conclusion. An indepth knowledge of actual and potential interactions with antineoplastic agents is critical for pharmacists in the management of patients with cancer. The ACB drug interaction index is an attempt to promote awareness of interactions with antineoplastic drugs and to encourage clinicians to investigate drug interactions during their treatment and management protocols.
Key Words: antineoplastic • interaction • oncology • pharmaceutical care • pharmacist
Journal of Oncology Pharmacy Practice, Vol. 9, No. 2-3,
87-107 (2003) This article has been cited by other articles:
|
|||||||||||||||
 |
|
|
 |
Sign In to gain access to subscriptions and/or personal tools.
